{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:49:30Z","timestamp":1747194570287,"version":"3.40.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with chronic kidney disease frequently face various nutritional and metabolic problems that necessitate the use of multiple medications. This multiple drug use can lead to several drug-related problems including adverse drug events, hospital admissions, poor medication adherence, harmful drug interactions, inadequate therapeutic outcomes, and death. Despite these challenges, there is a notable lack of studies on the extent of multiple drug use and its determinants among patients with chronic kidney disease in Ethiopia. This study aims to assess the magnitude of multiple drug use and identify the determinants of vulnerability among patients with chronic kidney disease in Ethiopia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A hospital-based cross-sectional study was conducted among patients with chronic kidney disease. Eligible participants were selected using a simple random sampling technique. Frequency and percentage calculations were performed for categorical variables, while means and standard deviations were used for continuous variables. The chi-square test and t-test were used to compare the proportions and means, respectively. Binary logistic regression was used to identify the determinants of multiple drug use, with statistical significance determined by a p-value of less than 0.05 and a 95% confidence interval. Guidelines and previous literature were utilized to assess the magnitude of multiple drug use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 230 patients were enrolled, with more than half being male. The overall magnitude of multiple drug use was 83.0%. Diuretics being the most frequently prescribed medication class followed by angiotensin converting enzyme inhibitors. Patients aged 65 years and above (AOR\u2009=\u20094.91 (95% CI 1.60-15.03)), CKD stage five (AOR)\u2009=\u20095.48 (95% CI 1.99\u201315.09)), and the presence of comorbid conditions (AOR)\u2009=\u20093.53 (95% CI 1.55\u20138.06)) were significantly associated with multiple drug use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Chronic kidney disease patients exhibited a high rate of multiple drug use. The presence of comorbid conditions, disease progression and older age are significant determinates of this vulnerability. Health care providers should pay particular attention to these factors to manage and mitigate the risks associated with multiple drug use.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-024-03773-x","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T21:01:46Z","timestamp":1728334906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Magnitude of multiple drug use and determinants of vulnerability among chronic kidney disease inpatients in Ethiopia: a multi-center study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3528-0703","authenticated-orcid":false,"given":"Tirsit Ketsela","family":"Zeleke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahel Belete","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Agegnew","family":"Wondm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bantayehu Addis","family":"Tegegne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"issue":"1","key":"3773_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/kisup.2012.77","volume":"3","author":"G Eknoyan","year":"2013","unstructured":"Eknoyan G, Lameire N, Eckardt K, Kasiske B, Wheeler D, Levin A, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney int. 2013;3(1):5\u201314.","journal-title":"Kidney int"},{"issue":"1","key":"3773_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Supplements. 2022;12(1):7\u201311.","journal-title":"Kidney Int Supplements"},{"issue":"1","key":"3773_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4103\/amhs.amhs_11_18","volume":"6","author":"OJ Fasipe","year":"2018","unstructured":"Fasipe OJ, Akhideno PE, Ibiyemi-Fasipe OB, Idowu AA. The burden of polypharmacy and pattern of comorbidities among chronic kidney disease patients in clinical practice. Archives Med Health Sci. 2018;6(1):40\u20137.","journal-title":"Archives Med Health Sci"},{"issue":"6","key":"3773_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1053\/ajkd.2000.19837","volume":"36","author":"O Heimb\u00fcrger","year":"2000","unstructured":"Heimb\u00fcrger O, Qureshi AR, Blaner WS, Berglund L, Stenvinkel P. Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. Am J Kidney Dis. 2000;36(6):1213\u201325.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3773_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/ndt\/gfu294","volume":"30","author":"S Titze","year":"2015","unstructured":"Titze S, Schmid M, K\u00f6ttgen A, Busch M, Floege J, Wanner C, et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German chronic kidney disease (GCKD) cohort. Nephrol Dialysis Transplantation. 2015;30(3):441\u201351.","journal-title":"Nephrol Dialysis Transplantation"},{"key":"3773_CR6","unstructured":"THIS HTC. Prevalence of comorbidities, polypharmacy and drug related problems among hospitalized patients with chronic kidney disease. 2023."},{"key":"3773_CR7","doi-asserted-by":"crossref","unstructured":"Mason NA, Bakus JL, editors. Strategies for reducing polypharmacy and other medication-related problems in chronic kidney disease. Seminars in dialysis. Wiley Online Library; 2010.","DOI":"10.1111\/j.1525-139X.2009.00629.x"},{"issue":"12","key":"3773_CR8","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1111\/bcp.13738","volume":"84","author":"SM Laville","year":"2018","unstructured":"Laville SM, Metzger M, Stengel B, Jacquelinet C, Combe C, Fouque D, et al. Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort. Br J Clin Pharmacol. 2018;84(12):2811\u201323.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3773_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/ckj\/sfz046","volume":"12","author":"IM Schmidt","year":"2019","unstructured":"Schmidt IM, H\u00fcbner S, Nadal J, Titze S, Schmid M, B\u00e4rthlein B, et al. Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German chronic kidney Disease study. Clin Kidney J. 2019;12(5):663\u201372.","journal-title":"Clin Kidney J"},{"key":"3773_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jclinepi.2018.10.014","volume":"106","author":"UT Kadam","year":"2019","unstructured":"Kadam UT, Roberts I, White S, Bednall R, Khunti K, Nilsson PM, et al. Conceptualizing multiple drug use in patients with comorbidity and multimorbidity: proposal for standard definitions beyond the term polypharmacy. J Clin Epidemiol. 2019;106:98\u2013107.","journal-title":"J Clin Epidemiol"},{"key":"3773_CR11","unstructured":"Varghese D, Ishida C, Koya HH. Polypharmacy. StatPearls [Internet]. 2022."},{"issue":"4","key":"3773_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/1753944716634579","volume":"10","author":"A Sutaria","year":"2016","unstructured":"Sutaria A, Liu L, Ahmed Z. Multiple medication (polypharmacy) and chronic kidney disease in patients aged 60 and older: a pharmacoepidemiologic perspective. Ther Adv Cardiovasc Dis. 2016;10(4):242\u201350.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"3773_CR13","first-page":"19","volume":"18","author":"M Liu","year":"2014","unstructured":"Liu M, Li X-C, Lu L, Cao Y, Sun R-R, Chen S, et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci. 2014;18:19.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"3773_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.nephro.2005.08.002","volume":"1","author":"E Riemer","year":"2005","unstructured":"Riemer E, Werling E, Kribs M, Hamman De Compte A, Dimitrov Y. Medical prescriptions in haemodialysis patients: critical analysis. N\u00e9phrologie Th\u00e9rapeutique. 2005;1(4):234\u201340.","journal-title":"N\u00e9phrologie Th\u00e9rapeutique"},{"issue":"11","key":"3773_CR15","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1503\/cmaj.080351","volume":"179","author":"A Levin","year":"2008","unstructured":"Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, et al. Guidelines for the management of chronic kidney disease. CMAJ. 2008;179(11):1154\u201362.","journal-title":"CMAJ"},{"issue":"1","key":"3773_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"DC Wheeler","year":"2017","unstructured":"Wheeler DC, Winkelmayer WC. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) foreword. Kidney Int Supplements. 2017;7(1):1\u201359.","journal-title":"Kidney Int Supplements"},{"issue":"5","key":"3773_CR17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1053\/j.ajkd.2017.05.025","volume":"70","author":"CF Whittaker","year":"2017","unstructured":"Whittaker CF, Fink JC. Deprescribing in CKD: the proof is in the process. Am J Kidney Dis. 2017;70(5):596\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"3773_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/MNH.0b013e328349c261","volume":"20","author":"NA Mason","year":"2011","unstructured":"Mason NA. Polypharmacy and medication-related complications in the chronic kidney disease patient. Curr Opin Nephrol Hypertens. 2011;20(5):492\u20137.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"12","key":"3773_CR19","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2215\/CJN.03940321","volume":"16","author":"H Kimura","year":"2021","unstructured":"Kimura H, Tanaka K, Saito H, Iwasaki T, Oda A, Watanabe S, et al. Association of polypharmacy with kidney disease progression in adults with CKD. Clin J Am Soc Nephrol. 2021;16(12):1797\u2013804.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3773_CR20","doi-asserted-by":"publisher","first-page":"1122898","DOI":"10.3389\/fphar.2023.1122898","volume":"14","author":"L Naseralallah","year":"2023","unstructured":"Naseralallah L, Khatib M, Al-Khulaifi A, Danjuma M. Prevalence and global trends of polypharmacy in patients with chronic kidney disease: a systematic review and meta-analysis. Front Pharmacol. 2023;14:1122898.","journal-title":"Front Pharmacol"},{"key":"3773_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/8238250","volume":"2021","author":"TK Zeleke","year":"2021","unstructured":"Zeleke TK, Birhan TY, Abdela OA. Medicine dose adjustment practice and associated factors among renally impaired patients in Amhara Regional State, Ethiopia. Int J Nephrol. 2021;2021:1\u20139.","journal-title":"Int J Nephrol"},{"key":"3773_CR22","doi-asserted-by":"publisher","first-page":"1116583","DOI":"10.3389\/fpubh.2023.1116583","volume":"11","author":"X Wang","year":"2023","unstructured":"Wang X, Yang C, Jiang J, Hu Y, Hao Y, Dong J-Y. Polypharmacy, chronic kidney disease, and mortality among older adults: a prospective study of National Health and nutrition examination survey, 1999\u20132018. Front Public Health. 2023;11:1116583.","journal-title":"Front Public Health"},{"issue":"1","key":"3773_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"issue":"1","key":"3773_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1681\/ASN.2020030384","volume":"32","author":"JT Kelly","year":"2021","unstructured":"Kelly JT, Su G, Zhang L, Qin X, Marshall S, Gonz\u00e1lez-Ortiz A, et al. Modifiable lifestyle factors for primary prevention of CKD: a systematic review and meta-analysis. J Am Soc Nephrol. 2021;32(1):239\u201353.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3773_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/0250-474X.102545","volume":"74","author":"M Rama","year":"2012","unstructured":"Rama M, Viswanathan G, Acharya LD, Attur R, Reddy P, Raghavan S. Assessment of drug-drug interactions among renal failure patients of nephrology ward in a south Indian tertiary care hospital. Indian J Pharm Sci. 2012;74(1):63.","journal-title":"Indian J Pharm Sci"},{"key":"3773_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5935\/0101-2800.20140006","volume":"36","author":"AB Marquito","year":"2014","unstructured":"Marquito AB, Fernandes NMS, Colugnati FAB, Paula RB. Identifying potential drug interactions in chronic kidney disease patients. Brazilian J Nephrol. 2014;36:26\u201334.","journal-title":"Brazilian J Nephrol"},{"issue":"2","key":"3773_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.pop.2008.01.008","volume":"35","author":"R Thomas","year":"2008","unstructured":"Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim care: Clin Office Pract. 2008;35(2):329\u201344.","journal-title":"Prim care: Clin Office Pract"},{"issue":"12","key":"3773_CR28","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1093\/ckj\/sfab120","volume":"14","author":"MJ van Oosten","year":"2021","unstructured":"van Oosten MJ, Logtenberg SJ, Hemmelder MH, Leegte MJ, Bilo HJ, Jager KJ, et al. Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls. Clin Kidney J. 2021;14(12):2497\u2013523.","journal-title":"Clin Kidney J"},{"key":"3773_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-020-1485-4","volume":"20","author":"C Roux-Marson","year":"2020","unstructured":"Roux-Marson C, Baranski JB, Fafin C, Exterman G, Vigneau C, Couchoud C, et al. Medication burden and inappropriate prescription risk among elderly with advanced chronic kidney disease. BMC Geriatr. 2020;20:1\u201312.","journal-title":"BMC Geriatr"},{"key":"3773_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:1\u201310.","journal-title":"BMC Geriatr"},{"issue":"4","key":"3773_CR31","first-page":"2","volume":"24","author":"V Sgnaolin","year":"2014","unstructured":"Sgnaolin V, Sgnaolin V, Engroff P, De Carli GA, Figueiredo AEPL. Assessment of used medications and drug-drug interactions among chronic renal failure patients. Scientia Med. 2014;24(4):2.","journal-title":"Scientia Med"},{"key":"3773_CR32","doi-asserted-by":"crossref","unstructured":"Al-Hajje A, Atoui F, Awada S, Rachidi S, Zein S, Salameh P, editors. Drug-related problems identified by clinical pharmacist\u2019s students and pharmacist\u2019s interventions. Annales pharmaceutiques fran\u00e7aises. Elsevier; 2012.","DOI":"10.1016\/j.pharma.2012.02.004"},{"key":"3773_CR33","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1007\/s11096-014-0001-3","volume":"36","author":"A Cabello-Muriel","year":"2014","unstructured":"Cabello-Muriel A, Gasc\u00f3n\u2013C\u00e1novas JJ, Urbieta-Sanz E, Iniesta-Naval\u00f3n C. Effectiveness of pharmacist intervention in patients with chronic kidney disease. Int J Clin Pharm. 2014;36:896\u2013903.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"3773_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ijmedinf.2015.02.005","volume":"84","author":"T Shemeikka","year":"2015","unstructured":"Shemeikka T, Bastholm-Rahmner P, Elinder C-G, V\u00e9g A, T\u00f6rnqvist E, Cornelius B, et al. A health record integrated clinical decision support system to support prescriptions of pharmaceutical drugs in patients with reduced renal function: design, development and proof of concept. Int J Med Informatics. 2015;84(6):387\u201395.","journal-title":"Int J Med Informatics"},{"issue":"2","key":"3773_CR35","first-page":"68","volume":"15","author":"C-A Yao","year":"2022","unstructured":"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. Int J Clin Exp Med. 2022;15(2):68\u201373.","journal-title":"Int J Clin Exp Med"},{"issue":"8","key":"3773_CR36","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.2215\/CJN.01030120","volume":"15","author":"SM Laville","year":"2020","unstructured":"Laville SM, Gras-Champel V, Moragny J, Metzger M, Jacquelinet C, Combe C, et al. Adverse drug reactions in patients with CKD. Clin J Am Soc Nephrol. 2020;15(8):1090\u2013102.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3773_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-015-0155-9","volume":"16","author":"H Getachew","year":"2015","unstructured":"Getachew H, Tadesse Y, Shibeshi W. Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. BMC Nephrol. 2015;16:1\u20139.","journal-title":"BMC Nephrol"},{"issue":"0","key":"3773_CR38","first-page":"49","volume":"8","author":"EA Onyedikachi","year":"2017","unstructured":"Onyedikachi EA, Ogochukwu AM, Chinwendu AK. Evaluation of drug-drug interactions among chronic kidney disease patients of nephrology unit in the University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu State. J Basic Clin Pharm. 2017;8(0):49\u201353.","journal-title":"J Basic Clin Pharm"},{"key":"3773_CR39","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11096-019-00811-9","volume":"41","author":"RN Okoro","year":"2019","unstructured":"Okoro RN, Farate VT. The use of nephrotoxic drugs in patients with chronic kidney disease. Int J Clin Pharm. 2019;41:767\u201375.","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"3773_CR40","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","volume":"175","author":"IA Scott","year":"2015","unstructured":"Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827\u201334.","journal-title":"JAMA Intern Med"},{"key":"3773_CR41","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s40266-018-0593-8","volume":"35","author":"LK Triantafylidis","year":"2018","unstructured":"Triantafylidis LK, Hawley CE, Perry LP, Paik JM. The role of deprescribing in older adults with chronic kidney disease. Drugs Aging. 2018;35:973\u201384.","journal-title":"Drugs Aging"},{"key":"3773_CR42","doi-asserted-by":"publisher","first-page":"205435812091265","DOI":"10.1177\/2054358120912652","volume":"7","author":"JG Marin","year":"2020","unstructured":"Marin JG, Beresford L, Lo C, Pai A, Espino-Hernandez G, Beaulieu M. Prescription patterns in dialysis patients: differences between hemodialysis and peritoneal dialysis patients and opportunities for deprescription. Can J Kidney Health Disease. 2020;7:2054358120912652.","journal-title":"Can J Kidney Health Disease"},{"key":"3773_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-020-2798-6","volume":"24","author":"G-j Zhao","year":"2020","unstructured":"Zhao G-j, Xu C, Ying J-c, L\u00fc W-b, Hong G-l, Li M-f, et al. Association between furosemide administration and outcomes in critically ill patients with acute kidney injury. Crit Care. 2020;24:1\u20139.","journal-title":"Crit Care"},{"issue":"19","key":"3773_CR44","doi-asserted-by":"publisher","first-page":"e009992","DOI":"10.1161\/JAHA.118.009992","volume":"7","author":"E Ku","year":"2018","unstructured":"Ku E, McCulloch CE, Vittinghoff E, Lin F, Johansen KL. Use of Antihypertensive agents and Association with risk of adverse outcomes in chronic kidney disease: focus on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J Am Heart Association. 2018;7(19):e009992.","journal-title":"J Am Heart Association"},{"issue":"1","key":"3773_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40885-023-00238-5","volume":"29","author":"W Jo","year":"2023","unstructured":"Jo W, Koh ES, Chung S. Therapeutic roles of thiazides and loop diuretics in blood pressure control and renal protection against chronic kidney disease. Clin Hypertens. 2023;29(1):14.","journal-title":"Clin Hypertens"},{"issue":"5","key":"3773_CR46","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jash.2012.07.004","volume":"6","author":"R Agarwal","year":"2012","unstructured":"Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 2012;6(5):299\u2013308.","journal-title":"J Am Soc Hypertens"},{"issue":"8","key":"3773_CR47","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(15)00123-0","volume":"3","author":"S-C Hung","year":"2015","unstructured":"Hung S-C, Chang Y-K, Liu J-S, Kuo K-L, Chen Y-H, Hsu C-C, et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol. 2015;3(8):605\u201314.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3773_CR48","unstructured":"Varghese D, Ishida C, Haseer Koya H. Polypharmacy. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright. 2022."},{"issue":"24","key":"3773_CR49","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1001\/jama.2008.892","volume":"300","author":"DM Qato","year":"2008","unstructured":"Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867\u201378.","journal-title":"JAMA"},{"issue":"4","key":"3773_CR50","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.amjopharm.2007.12.002","volume":"5","author":"ER Hajjar","year":"2007","unstructured":"Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345\u201351.","journal-title":"Am J Geriatr Pharmacother"},{"key":"3773_CR51","unstructured":"Gellad WF, Grenard JL, McGlynn EA. A review of barriers to medication adherence: a framework for driving policy options. 2009."},{"issue":"2","key":"3773_CR52","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cger.2012.01.008","volume":"28","author":"ZA Marcum","year":"2012","unstructured":"Marcum ZA, Gellad WF. Medication adherence to multidrug regimens. Clin Geriatr Med. 2012;28(2):287\u2013300.","journal-title":"Clin Geriatr Med"},{"key":"3773_CR53","doi-asserted-by":"crossref","unstructured":"Zeleke TK, Kemal LK, Mehari EA, Sema FD, Seid AM, Mekonnen GA et al. Nephrotoxic drug burden and predictors of exposure among patients with renal impairment in Ethiopia: a multi-center study. Heliyon. 2024;10(2).","DOI":"10.1016\/j.heliyon.2024.e24618"},{"issue":"4","key":"3773_CR54","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/ki.2015.228","volume":"88","author":"M Tonelli","year":"2015","unstructured":"Tonelli M, Wiebe N, Guthrie B, James MT, Quan H, Fortin M, et al. Comorbidity as a driver of adverse outcomes in people with chronic kidney disease. Kidney Int. 2015;88(4):859\u201366.","journal-title":"Kidney Int"},{"key":"3773_CR55","first-page":"98","volume":"289","author":"L Morin","year":"2018","unstructured":"Morin L, Johnell K, Laroche M-L, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018;289:98.","journal-title":"Clin Epidemiol"},{"issue":"5","key":"3773_CR56","doi-asserted-by":"publisher","first-page":"465","DOI":"10.7861\/clinmedicine.16-5-465","volume":"16","author":"RA Payne","year":"2016","unstructured":"Payne RA. The epidemiology of polypharmacy. Clin Med. 2016;16(5):465.","journal-title":"Clin Med"},{"issue":"23","key":"3773_CR57","doi-asserted-by":"publisher","first-page":"e33984","DOI":"10.1097\/MD.0000000000033984","volume":"102","author":"C Elendu","year":"2023","unstructured":"Elendu C, Elendu RC, Enyong JM, Ibhiedu JO, Ishola IV, Egbunu EO, et al. Comprehensive review of current management guidelines of chronic kidney disease. Medicine. 2023;102(23):e33984.","journal-title":"Medicine"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03773-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03773-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03773-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T09:03:58Z","timestamp":1728378238000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03773-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3773"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03773-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the Declaration of Helsinki, and each participant gave informed consent after receiving thorough details about the study. The ethical committee of the University of Gondar College of Medicine and Health Sciences, Department of Clinical Pharmacy provided ethical clearance. Additionally, we obtained the necessary permissions and approvals from the administrations of the three participating hospitals: Debre Markos Comprehensive Specialized Hospital, Felege Hiwot Specialized Comprehensive Hospital, and University of Gondar Specialized Comprehensive Hospital. Clinical trial number: not applicable. Furthermore, no identifiable details were incorporated in the questionnaire in order to safeguard the privacy of the respondents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"332"}}